We are engaged in the distribution and supply of a diversified portfolio of solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials and nutraceuticals. With over two decades of operational experience in the chemical industry, we have developed sourcing relationships with domestic and international suppliers, enabling us to procure a broad range of chemical products and supply them to traders, distributors and customers operating across multiple end-use industries. Our products are supplied to customers operating in pharmaceutical, agrochemical, specialty chemical, petrochemical, industrial and automotive sectors, as well as paints and coatings, printing inks and packaging applications. Our sourcing capabilities, supported by our distribution network and experience in procurement, logistics coordination and supply chain management, enable us to efficiently procure and supply chemical products across domestic and international markets. We support our customers throughout their procurement process by assisting with purchase planning, consolidating demand, and leveraging our relationships with domestic and international suppliers. We negotiate key commercial terms, including pricing, product specifications, quantities, and delivery schedules, while also managing the end-to-end supply chain, encompassing storage, handling, and logistics support. This integrated approach enables us to provide reliable, timely and cost-effective supply solutions to our customers As per the D&B Report, during the last three Fiscals and the period ended December 31, 2025, our Company supplied an aggregate of approximately 8,52,765.25 MT of chemical products to 3,034 customers. Our operations are supported by a distribution infrastructure comprising various warehouses and storage facilities located across Bhiwandi, Maharashtra and Kandla, Gujarat and a sourcing network of 1,277 suppliers.
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 95,75,700 crores |
| Non-Institutional Investors (NIIs) | 35% | 67,02,990 crores |
| Retail Individual Investors (RIIs) | 15% | 28,72,710 crores |
Ujin Pharma’s total income 0.00 by 0.00% and total expenses 0.00 by 0.00%, resulting in an EBITDA 13.09 by -55.81% and a profit after tax (PAT) 0.00 by 0.00% between March 31, 2025 and March 31, 2026.
13.0931 March 2026 | 29.6231 March 2025 | 35.4531 March 2024 |
35.45
32
28
25
21
18
14
11
7
4
0.00
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| -- | -- | -- |
| Issue Composition: | |
|---|---|
| Face Value | ₹10 per share |
| Total Issue Size | 1,91,51,400 shares (aggregating up to To be announced) |
| Fresh Issue | 11,86,910 shares (aggregating up to ₹1,18,69,100 crores) |
| Offer for Sale | 7,28,230 shares of ₹10 (aggregating up to ₹72,82,300 crores) |
| Issue Type | Book Building IPO |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 98.5 shares |
| Post-Issue Shareholding | 0 shares |
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Ujin Pharma ipo has been designed to ensure broad participation while maintaining optimal price discovery.
610/6th Floor Neelkanth Corporate Park Kirol Road Mumbai
Kfin Technologies Ltd.
| Book Running Lead Manager(s) |
|---|
| SMC Capitals Ltd | Marwadi Chandarana Intermediaries Brokers Pvt Ltd |